// App-Quantinova.ai

BSH19‐OR‐008 : A Retrospective Real World Evidence Study To Review The Current Treatment Pathways for Myelofibrosis From Across The United Kingdom (The REALISM UK Study)

Researchers

Presenter

  • A. Mead

Principal Investigators

  • N. Butt

  • W. Nagi

  • A. Whiteway

  • S. Kirkpatrick

  • C. Rinaldi

  • C. Roughley

  • S. Ackroyd

  • J. Ewing

  • P. Neelakantan

  • M. Garg

  • C. Harrison

  • D. Tucker

  • S. Collington

  • G. Chiu

  • J. Hickey

  • T. Somervaille

Medical Centers

  • Oxford University Hospitals NHS Trust, Oxford,

  • The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool

  • Mid Essex Hospital Services, Chelmsford

  • North Bristol NHS Trust, Bristol, UK

  • United Lincolnshire Hospitals NHS trust

  • East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom

  • Bradford Teaching Hospitals NHS Foundation Trust, Bradford

  • Heart ofEngland Foundation NHS Trust, Birmingham, UK

  • The Royal Berkshire NHS Foundation Trust,Reading, UK

  • University Hospitals Leicester NHS Trust, Leicester

  • Guys and St Thomas Hospitals NHS Foundation Trust, London, UK

  • Torbay and South Devon NHS Foundation Trust, Torbay

  • Novartis Pharmaceuticals UK Ltd., Camberley, UK

  • pH Associates, Marlow

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Myelofibrosis

  • Congestive heart failure

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxycarbamide

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved